Wider loss overshadows revenue. BridgeBio Pharma reported a loss of $1 per share for Q4 2025, wider than the expected loss of $0.62 per share by 50.6%. The biotechnology company’s net loss reached $192.9 million for the quarter. Despite the earnings miss, shares surged 13.2% to $74.32 on volume of 6.1 million shares, suggesting investors focused on other metrics beyond the bottom line.
Revenue climbs amid operational losses. The company generated $154.2 million in revenue for the quarter, with gross profit of $146.1 million against cost of revenue of just $8.1 million, yielding a gross margin of 94.7%. Operating loss totaled $128.4 million, while EBITDA came in at negative $143.0 million. Research and development expenses consumed $116.4 million, with selling, general and administrative costs adding another $158.1 million. The company burned $56.4 million in operating cash flow and $56.5 million in free cash flow during the quarter.
Balance sheet shows leverage. BridgeBio closed the quarter with $570.1 million in cash and cash equivalents against total debt of $1.86 billion. Stockholders’ equity stood at negative $2.09 billion, reflecting accumulated losses of $3.82 billion. Working capital of $509.8 million provides near-term liquidity. The company’s $14.4 billion market capitalization suggests investors are pricing in significant future revenue potential despite current losses.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.